Biopharmaceutical company Aridis Pharmaceuticals Inc (Nasdaq:ARDS) stated on Friday that its CEO, Dr Vu Truong, will participate in Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19" to be held on 30 June 2020 at 11:00 ET
The company said it has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening ventilator associated pneumonia (VAP) and preclinical stage antiviral mAbs.
In addition, the company's pipeline also includes AR-701 (COVID-19), a fully human mAb cocktail discovered from convalescent COVID-19 patients that are directed at multiple envelope proteins on SARS-CoV-2. AR-201 (RSV infection). The AR-201 is a fully human IgG1 mAb out-licensed preclinical programme aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).
Entera Health wins IRB approval for launch of COVID-19 clinical trial in Spain
US FDA approves a new test that detects both flu and COVID-19
Liminal BioSciences Launches Collection of Convalescent Plasma from COVID-19 Recovered Donors
US FDA Distributes First Round of SARS-CoV-2 Reference Panel Materials
Anivive begins two pre-clinical studies of GC376 for the treatment of COVID-19
Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV
Laboratory Studies Confirm the Effectiveness of Betadine Gargle and Mouthwash Against COVID-19 Virus